ACE2 and COVID-19: Positron emission tomography (PET) utilizes radioligands to interrogate disease‐relevant biomarkers or pathways providing quantitative spatial distribution of physiologically relevant targets with exquisite sensitivity.[20, 21] With the long‐term aim to determine the effects of ACE2 expression on SARS‐CoV‐2 infection and COVID‐19 severity, we initiated this study to develop 64Cu and 68Ga‐labeled peptides to specifically targeting ACE2.